Table 2.
Characteristics of patients receiving second-line cabazitaxel versus second-line androgen receptor-targeted therapy at initiation of first-line docetaxel therapy
| Characteristics | Second-line therapy received | p value | |
|---|---|---|---|
| Cabazitaxel N = 123 |
AR-targeted therapy N = 506 |
||
| Age, years, mean ± SD (median) | 70.8 ± 9.3 (72.0) | 71.6 ± 9.0 (72.0) | 0.503 |
| Age, n (%) | |||
| <65 years | 29 (23.6) | 109 (21.5) | 0.625 |
| 65–74 years | 46 (37.4) | 190 (37.5) | 0.975 |
| ≥75 years | 48 (39.0) | 207 (40.9) | 0.703 |
| ECOG performance status, n (%) | |||
| 0 | 24 (19.5) | 74 (14.6) | 0.180 |
| 1 | 11 (8.9) | 62 (12.3) | 0.304 |
| 2 | 2 (1.6) | 17 (3.4) | 0.314 |
| 3 | 1 (0.8) | 2 (0.4) | 0.546 |
| Unknown | 85 (69.1) | 351 (69.4) | 0.955 |
| Number of metastases, mean ± SD (median) | 1.1 ± 0.3 (1.0) | 1.1 ± 0.4 (1.0) | 0.505 |
| Bone metastasis, n (%) | 82 (66.7) | 296 (58.5) | 0.097 |
| Visceral metastasis, n (%) | 7 (5.7) | 20 (4.0) | 0.394 |
| Lymph node metastasis, n (%) | 3 (2.4) | 29 (5.7) | 0.136 |
| Unknown, n (%) | 38 (30.9) | 193 (38.1) | 0.135 |
| PSA, ng/mL, mean ± SD (median) | 359.7 ± 1211.2 (85.3) | 262.3 ± 962.8 (63.4) | 0.193 |
| ALP, u/L, mean ± SD (median) | 231.1 ± 233.9 (139.0) | 206.4 ± 269.6 (111.0) | 0.039* |
| LDH, u/L, mean ± SD (median) | 373.8 ± 248.0 (256.0) | 333.2 ± 448.1 (222.0) | 0.048* |
| Albumin, g/dL, mean ± SD (median) | 3.8 ± 0.4 (3.9) | 3.9 ± 0.5 (3.9) | 0.219 |
| Hemoglobin, g/dL, mean ± SD (median) | 11.7 ± 1.5 (11.9) | 11.7 ± 1.6 (11.7) | 0.999 |
| Halabi risk score, mean ± SD (median)a | 127.6 ± 51.8 (126.7) | 126.1 ± 50.4 (121.6) | 0.243 |
| Low risk, n (%) | 70 (56.9) | 325 (64.2) | 0.132 |
| Intermediate risk, n (%) | 43 (35.0) | 139 (27.5) | 0.100 |
| High risk, n (%) | 10 (8.1) | 42 (8.3) | 0.951 |
| Opioid use in prior 365 days, n (%) | 39 (31.7) | 136 (26.9) | 0.284 |
| Duration of first-line therapy, months, mean ± SD (median) | 5.4 ± 4.4 (4.2) | 5.2 ± 4.4 (4.2) | 0.548 |
AR androgen receptor, ALP alkaline phosphatase, ECOG Eastern Cooperative Oncology Group, LDH lactate dehydrogenase, PSA prostate-specific antigen, SD standard deviation
aBased on Halabi et al. [18]
* Denotes significant p value at the 5% level